GALDERMA
Galderma, a global leader focused on meeting the world's increasing skin health needs, announced that it has enrolled the first patients in a new Phase 3 clinical study with nemolizumab, an investigational therapy in adult patients with moderate-to-severe atopic dermatitis.
This study is a randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of nemolizumab in subjects with moderate-to-severe atopic dermatitis.
Nemolizumab is a first-in-class investigational monoclonal antibody that blocks signaling of IL-31, a cytokine that plays a key role in the pathogenesis of moderate-to-severe atopic dermatitis. Atopic dermatitis is a serious, chronic form of eczema associated with a high burden of disease linked to itch, sleep deprivation and significant quality of life impairment.
“We are advancing the development of nemolizumab as planned. The Phase 2 results showed clear clinical benefits, adding to the growing scientific evidence that the IL-31 pathway may be an important driver in atopic dermatitis. We are committed to continuing our work to bring new therapies to patients with moderate-to-severe atopic dermatitis,” said Thibaud Portal PhD, Galderma Global Vice President, Prescription medicines.
Earlier this year, Galderma presented the final results from the Phase 2b study of nemolizumab in patients with moderate-to-severe atopic dermatitis at the 2019 American Academy of Dermatology Annual Meeting late-breaking session and published in the Journal of Allergy and Clinical Immunology in August 20191
About the IL-31 Pathway and Atopic Dermatitis
Moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema, is a systemic inflammatory disease characterized by an allergic response driven by a subset of immune cells called Type 2 helper T cells, or Th2 cells. IL-31, a cytokine released by Th2 cells, is involved in AD associated pruritus by interacting with IL-31 receptor alpha expressed by neuron. IL-31 is also thought to play a role in AD skin inflammation and AD skin barrier impairment. Moderate-to-severe forms of AD can be characterized by pronounced cutaneous dryness, and skin lesions marked by redness, infiltration/papulation, crusting/oozing, and lichenification, with periods of lesion exacerbation accompanied by intense itching, scratching, and skin damage that can lead to secondary infections. Moderate-to-severe AD can negatively impact patients’ lives and is associated with a high burden to patients particularly with itching, sleep deprivation and depression.
About Nemolizumab
Nemolizumab, a first-in-class humanized monoclonal antibody, is directed against the IL-31R alpha, which blocks signaling from - IL-31. Nemolizumab, initially developed by Chugai Pharmaceutical Co., Ltd., was subsequently licensed to Galderma in 2016. Nemolizumab is an investigational agent under clinical development and its safety and efficacy have not been fully evaluated by any regulatory authority.
About Galderma
Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com
References
1. Silverberg JI, et al., Phase 2b Randomized Study of Nemolizumab in Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus, Journal of Allergy and Clinical Immunology 2019, doi: https://doi.org/10.1016/j.jaci.2019.08.013 .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191010005291/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Allshares Acquires U.S. Market Leader Stock & Option Solutions, Solidifying Its Position as a Global Leader in Equity Ownership Management21.1.2026 12:00:00 CET | Press release
Allshares, a global provider of equity ownership management software and services, today announced the acquisition of Stock & Option Solutions (“SOS” or the “Company”), a U.S.-based specialist in end-to-end equity compensation and plan administration. Stock & Option Solutions brings a track record of supporting the full life cycle of equity and compensation plan administration. Recognized as one of the Inc. 5000 fastest-growing companies in 2022, the Company has built a strong reputation for supporting organizations across the United States, from early-stage startups to large enterprises. Its platform-agnostic service model enables clients to optimize complex incentive structures across major equity technology systems. This acquisition marks a strategic milestone in Allshares’ expansion, establishing the U.S. as Allshares’ largest and fastest-growing market. By integrating SOS’ deep U.S. expertise, Allshares strengthens its ability to deliver seamless ownership management for clients o
WEF26: ‘Human Capital Is the Key Driver of Economic Competitiveness’21.1.2026 10:33:00 CET | Press release
For economies to remain competitive in the future, they must prioritize investments in human capital, Her Royal Highness Princess Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States of America, told the World Economic Forum (WEF) Annual Meeting 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120585206/en/ Her Royal Highness Princess Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States of America, speaks on human capital and youth empowerment during the opening Saudi House session at the World Economic Forum Annual Meeting 2026 (Photo: AETOSWire) Speaking on a Saudi House panel, HRH commented: “Human capital today is the key driver if you want a competitive modern economy.” She added: “If you empower people and you give them the space to lead, they will take that drive and they will deliver. And when you place the right people in the right place at the r
BPP Signals Next Era of Growth, Unveiling New Global Parent Brand: Lyceum Education Group21.1.2026 10:03:00 CET | Press release
The creation of the new brand reflects the unique global reach of eleven leading education businesses across the UK, Europe, North America and Australia Today marks the launch of Lyceum Education Group, the new parent brand for 11 leading specialist education businesses across the UK, mainland Europe, Canada and Australia. Lyceum Education Group brings together leading specialist education providers, delivering a diverse portfolio of programmes to benefit learners and businesses globally. From its beginnings as BPP almost 50 years ago, to the creation of the Lyceum Education Group brand today, the move reflects the transition to become a leading, global education group, which will be the second largest post-secondary provider in the UK, and the fourth largest in Europe. Since its acquisition by TDR Capital in 2021, the Group has been acquiring new brands which encompass increased specialisms, diversifying its product ranges and entering new global markets. A clear focus for Lyceum Educ
Ageneau Group Chooses Generix WMS to Boost Growth21.1.2026 09:00:00 CET | Press release
Generix, a global business software company offering an expansive portfolio of SaaS solutions for supply chain, finance, commerce, and B2B integration, announces that Ageneau Group, a French transportation, logistics, and training company, has chosen Generix WMS and TradeXpress to modernize operational processes at its Angers (Trélazé) site, which has a covered area of 9,000 m² and state-of-the-art technological equipment, including automated guided vehicles (AGVs). “We needed a powerful and scalable tool that was in line with our values of cohesion, respect, and innovation. Generix was able to meet 100% of our specifications and support us with transparency and expertise,” said Arnaud Ageneau, co-director of processes, purchasing, and IT at the Ageneau Group. To support its growth and meet the changing needs of its customers, the Ageneau Group was looking for a solution capable of digitizing its operations, optimizing its flows, and providing advanced logistics to its teams. The group
International Zinc Association Partners With Pharmanova to Save Children in Zambia21.1.2026 09:00:00 CET | Press release
Zinc Saves Kids, a global child‑health initiative of the International Zinc Association (IZA), has announced a new partnership with leading Zambian pharmaceutical manufacturer Pharmanova Zambia Limited to expand access to life‑saving zinc treatments for children across Zambia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121178091/en/ Life-saving zinc-supplementation and oral rehydration salts kits are proactively distributed to Zambian children through the works of the International Zinc Association, Pharmanova, and the Zambian Ministries of Health and Education. The collaboration was formally celebrated during a ceremony in Lusaka with the Zambian Ministry of Health, Pharmanova Zambia Limited, and IZA represented by Environment Health & Sustainability Director Dr. Eric Van Genderen. IZA and Pharmanova have united in an effort to scale up treatment for childhood diarrhea using zinc, an essential micronutrient that stre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom